News
Drug discovery technology start-up DyNAbind secures seed financing
DyNAbind’s Dynamic DNA-Encoded Library technology platform allows hundreds of millions of chemical structures to be simultaneously screened and optimized against a potential drug target protein. This innovation continues to be driven forward with investment from the High-Tech Gründerfonds (HTGF), Technologiegründerfonds Sachsen (TGFS) and existing shareholder TUDAG – TU Dresden AG.Dresden: Neues Innovationszentrum für Startups, Forschung und Technologie eröffnet
Wirtschaftsstandort Görlitz wächst: Neue Industrieansiedlung in Görlitz gestartet
DyNAbind bietet ab sofort einen Screening-Kit mit einer Fragment-basierten DNA-kodierten Bibliothek an und gewinnt Merck KGaA als Vertriebspartner
Successful start of the first workshop of the event series "bionection meets…" about Cancer Imaging Research with OncoRay
Sächsische Staatspreise für Innovation und Gründer: Die Nominierten stehen fest
Martin Dulig: „Sachsen gehört zu den innovativsten Regionen in Europa – das wollen wir zeigen.“Worldwide first and only shotgun lipidomics service provider with official GMP certificate
DyNAbind und Omass Therapeutics schließen Kooperationsabkommen zur Erforschung neuer Arzneimittel
Die DyNAbind GmbH und Omass Therapeutics haben ein Kooperationsabkommen zur Erforschung neuer Arzneimittel auf der Basis von Fragmenten und kleinen Molekülen abgeschlossen. Im Mittelpunkt stehen dabei Transmembranproteine die mit klassischen Methoden nur schwer zu adressieren sind.c-LEcta develops highly efficient manufacturing process for active cosmetic ingredient
c-LEcta has developed a new and highly efficient manufacturing process for an active ingredient in body care products. c-LEcta’s fermentative production process enables much more efficient industrial production of this active ingredient, which has a proven skin protection effect. It is used, for example, in anti-aging and skin protection products and opens up another multi-billion-euro market for c-LEcta.
For the fermentative manufacturing process, c-LEcta's scientists developed a new microorganism using targeted changes in the metabolic properties, which contributes to exceptionally high yields in the production of active ingredients.
Dr. Andreas Buthe, Head of Innovation and Senior Business Development Manager at c-LEcta, played a key role in the development: “We are proud to have again been able to demonstrate the innovative power of our unique technology platform with this manufacturing process. Following the successful establishment of the process, we are now beginning to implement industrial scale-up and commercialization.”
Due to the cost-intensive manufacturing process, the active ingredient has so far only been contained in expensive premium products. c-LEcta’s optimized bioprocess now makes it possible to use the active ingredient in cheaper cosmetics and to provide a wide range of products with versatile care properties.
“With the development of this bioprocess, we have not only reached an important technical and scientific milestone. We are also providing the cosmetics industry with a more cost-effective source of supply, thereby contributing to a wider availability of the scientifically proven benefits of the active ingredient for consumers in everyday use,” explains Dr. Marc Struhalla, co-founder and CEO of c-LEcta. The development of c-LEcta’s own products, which can be marketed by c-LEcta directly to various customers worldwide, is part of the Leipzig-based company’s growth strategy. The second pillar are strategic, equal partnerships with established industrial companies in which c-LEcta makes targeted use of the potential of global megatrends. c-LEcta attributes an annual sales potential in the double-digit million-euro range to the marketing of the body care active ingredient in the medium term.
Quelle: Pressemitteilung von c-LEcta vom 6. März 2019
